参考文献/References:
[1] World Health Organization.WHO Coronavirus disease(COVID-2019)Dashboard[EB/OL].(2021-12-09)[2021-12-09].https://covid19.who.int.
[2] Guan WJ,Ni ZY,Hu Y,et al.Clinical Characteristics of Coronavirus Disease 2019 in China[J].N Engl J Med,2020,382(18):1708-1720.DOI:10.1056/NEJMoa2002032.
[3] Wu H,Lau ESH,Ma RCW,et al.Secular trends in all-cause and cause-specific mortality rates in people with diabetes in Hong Kong,2001-2016:a retrospective cohort study[J].Diabetologia,2020,63(4):757-766.DOI:10.1007/s00125-019-05074-7.
[4] Allard R,Leclerc P,Tremblay C,et al.Diabetes and the severity of pandemic influenza A(H1N1)infection[J].Diabetes Care,2010,33(7):1491-1493.DOI:10.2337/dc09-2215.
[5] Yang JK,Feng Y,Yuan MY,et al.Plasma glucose levels and diabetes are independent predictors for mortality and morbidity in patients with SARS[J].Diabet Med,2006,23(6):623-628.DOI:10.1111/j.1464-5491.2006.01861.x.
[6] Fadini GP,Morieri ML,Longato E,et al.Prevalence and impact of diabetes among people infected with SARS-CoV-2[J].J Endocrinol Invest,2020,43(6):867-869.DOI:10.1007/s40618-020-01236-2.
[7] Li Y,Teng D,Shi X,et al.Prevalence of diabetes recorded in mainland China using 2018 diagnostic criteria from the American Diabetes Association:national cross sectional study[J].BMJ,2020,369:m997.DOI:10.1136/bmj.m997.
[8] Longato E,Di Camillo B,Sparacino G,et al.Diabetes diagnosis from administrative claims and estimation of the true prevalence of diabetes among 4.2 million individuals of the Veneto region(North East Italy)[J].Nutr Metab Cardiovasc Dis,2020,30(1):84-91.DOI:10.1016/j.numecd.2019.08.017.
[9] Frydrych LM,Bian G,O'Lone DE,et al.Obesity and type 2 diabetes mellitus drive immune dysfunction,infection development,and sepsis mortality[J].J Leukoc Biol,2018,104(3):525-534.DOI:10.1002/JLB.5VMR0118-021RR.
[10] Knapp S.Diabetes and infection:is there a link--A mini-review[J].Gerontology,2013,59(2):99-104.DOI:10.1159/000345107.
[11] Guo W,Li M,Dong Y,et al.Diabetes is a risk factor for the progression and prognosis of COVID-19[J].Diabetes Metab Res Rev,2020,e3319.DOI:10.1002/dmrr.3319.
[12] Pal R,Bhadada SK.COVID-19 and diabetes mellitus:An unholy interaction of two pandemics[J].Diabetes Metab Syndr,2020,14(4):513-517.DOI:10.1016/j.dsx.2020.04.049.
[13] Letko M,Marzi A,Munster V.Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses[J].Nat Microbiol,2020,5(4):562-569.DOI:10.1038/s41564-020-0688-y.
[14] Imai Y,Kuba K,Rao S,et al.Angiotensin-converting enzyme 2 protects from severe acute lung failure[J].Nature,2005,436(7047):112-116.DOI:10.1038/nature03712.
[15] Zhou J,Tan J.Diabetes patients with COVID-19 need better blood glucose management in Wuhan,China[J].Metabolism,2020,107:154216.DOI:10.1016/j.metabol.2020.154216.
[16] Ren H,Yang Y,Wang F,et al.Association of the insulin resistance marker TyG index with the severity and mortality of COVID-19[J].Cardiovasc Diabetol,2020,19(1):58.DOI:10.1186/s12933-020-01035-2.
[17] Li J,Wang X,Chen J,et al.COVID-19 infection may cause ketosis and ketoacidosis[J].Diabetes Obes Metab,22(10):1935-1941.DOI:10.1111/dom.14057.
[18] Bindom SM,Hans CP,Xia H,et al.Angiotensin I-converting enzyme type 2(ACE2)gene therapy improves glycemic control in diabetic mice[J].Diabetes,2010,59(10):2540-8.DOI:10.2337/db09-0782.
[19] Yang JK,Lin SS,Ji XJ,et al.Binding of SARS coronavirus to its receptor damages islets and causes acute diabetes[J].Acta Diabetol,2010,47(3):193-9.DOI:10.1007/s00592-009-0109-4.
[20] Lyu J,Imachi H,Fukunaga K,et al.Angiotensin II induces cholesterol accumulation and impairs insulin secretion by regulating ABCA1 in beta cells[J].J Lipid Res,2018,59(10):1906-1915.DOI:10.1194/jlr.M085886.
[21] Szymczak-Pajor I,S'liwińska A.Analysis of association between Vitamin D deficiency and insulin resistance[J].Nutrients,2019,11(4):794.DOI:10.3390/nu11040794.
[22] Chen D,Li X,Song Q,et al.Assessment of hypokalemia and clinical characteristics in patients with coronavirus disease 2019 in Wenzhou,China[J].JAMA Netw Open,2020,3(6):e2011122.DOI:10.1001/jamanetworkopen.2020.11122.
[23] Rowe JW,Tobin JD,Rosa RM,et al.Effect of experimental potassium deficiency on glucose and insulin metabolism[J].Metabolism,1980,29(6):498-502.DOI:10.1016/0026-0495(80)90074-8.
相似文献/References:
[1]李春睿,王静,陈峰,等.GLP-1受体激动剂对糖尿病患者肾功能的影响[J].国际内分泌代谢杂志,2014,(06):401.[doi:10.3760/cma.j.issn.1673-4157.2014.06.011]
Li Chunrui*,Wang Jing,Chen Feng,et al.Effects of GLP-1 receptor agonists on renal function of diabetics[J].International Journal of Endocrinology and Metabolism,2014,(01):401.[doi:10.3760/cma.j.issn.1673-4157.2014.06.011]
[2]黄珊珊,鲁一兵.长链非编码RNA与糖尿病[J].国际内分泌代谢杂志,2015,(04):271.[doi:10.3760/cma.j.issn.1673-4157.2015.04.016]
Huang Shanshan*,Lu Yibing..Long non-coding RNA and diabetes mellitus[J].International Journal of Endocrinology and Metabolism,2015,(01):271.[doi:10.3760/cma.j.issn.1673-4157.2015.04.016]
[3]高瑞霄,姚朱华,冯凭,等.尿8-羟基脱氧鸟苷在2型糖尿病及糖尿病合并冠心病患者中的临床意义[J].国际内分泌代谢杂志,2014,(05):295.[doi:10.3760/cma.j.issn.1673-4157.2014.05.002]
Gao Ruixiao*,Yao Zhuhua,Feng Ping,et al.The clinical significance of urinary 8-hydroxy deoxyguanosine in patients with type 2 diabetes mellitus and diabetic patients with coronary heart disease[J].International Journal of Endocrinology and Metabolism,2014,(01):295.[doi:10.3760/cma.j.issn.1673-4157.2014.05.002]
[4]郑佳,肖新华.葡萄糖稳态的中枢调控作用机制
——2014年美国糖尿病协会“杰出科学成就奖”
演讲报告解读[J].国际内分泌代谢杂志,2014,(05):305.[doi:10.3760/cma.j.issn.1673-4157.2014.05.004]
Zheng Jia,Xiao Xinhua.The mechanisms of central nervous system in the control of glucose homeostasis--A summary of 2014 ADA "Outstanding Scientific Achievement Award" Lecture[J].International Journal of Endocrinology and Metabolism,2014,(01):305.[doi:10.3760/cma.j.issn.1673-4157.2014.05.004]
[5]唐勤,邵莉.蛋白乙酰化与胰岛素分泌[J].国际内分泌代谢杂志,2014,(05):313.[doi:10.3760/cma.j.issn.1673-4157.2014.05.007]
Tang Qin,Shao Li..Protein acetylation and insulin secretion[J].International Journal of Endocrinology and Metabolism,2014,(01):313.[doi:10.3760/cma.j.issn.1673-4157.2014.05.007]
[6]卢婷婷,任思佳,沈捷.人群迁徙对糖尿病患病率的影响及其相关因素[J].国际内分泌代谢杂志,2014,(05):327.[doi:10.3760/cma.j.issn.1673-4157.2014.05.011]
Lu Tingting,Ren Sijia,Shen Jie..Impact of migration on prevalence of diabetes and risk factors[J].International Journal of Endocrinology and Metabolism,2014,(01):327.[doi:10.3760/cma.j.issn.1673-4157.2014.05.011]
[7]包薇萍,陈国芳,刘超.DPP-4抑制剂的肾保护作用[J].国际内分泌代谢杂志,2014,(05):337.[doi:10.3760/cma.j.issn.1673-4157.2014.05.014]
Bao Weiping,Chen Guofang,Liu Chao..Renal protective effects of dipeptidyl peptidase-4 inhibitors[J].International Journal of Endocrinology and Metabolism,2014,(01):337.[doi:10.3760/cma.j.issn.1673-4157.2014.05.014]
[8]孟庆冬,陶红.巨噬细胞凋亡与糖尿病动脉粥样硬化[J].国际内分泌代谢杂志,2014,(05):340.[doi:10.3760/cma.j.issn.1673-4157.2014.05.015]
Meng Qingdong,Tao Hong..Macrophage apoptosis and diabetic atherosclerosis[J].International Journal of Endocrinology and Metabolism,2014,(01):340.[doi:10.3760/cma.j.issn.1673-4157.2014.05.015]
[9]赵荷珺 洪天配.胰高血糖素样肽-1类药物与胰腺安全性[J].国际内分泌代谢杂志,2015,(05):319.[doi:DOI:10.3760/cma.j.issn.1673-4157.2015.05.008]
Zhao Hejun*,Hong Tianpei..Glucagon-like peptide-1-based therapies and pancreatic safety[J].International Journal of Endocrinology and Metabolism,2015,(01):319.[doi:DOI:10.3760/cma.j.issn.1673-4157.2015.05.008]
[10]吕丹 李晓思 陈树春 王泽普.Betatrophin:糖尿病再生治疗的新希望[J].国际内分泌代谢杂志,2015,(05):351.[doi:DOI:10.3760/cma.j.issn.1673-4157.2015.05.016]
Lyu Dan*,Li Xiaosi,Chen Shuchun,et al.Betatrophin:new hope for regeneration therapy of diabetes[J].International Journal of Endocrinology and Metabolism,2015,(01):351.[doi:DOI:10.3760/cma.j.issn.1673-4157.2015.05.016]
[11]宋博,滕卫平.糖尿病不同降糖药物与新型冠状病毒肺炎的相关性研究进展[J].国际内分泌代谢杂志,2022,42(03):191.[doi:10.3760/cma.j.cn121383-20210326-03036]
Song Bo,Teng Weiping..Research progress on the relationship between different hypoglycemic drugs and COVID-19 in diabetes mellitus[J].International Journal of Endocrinology and Metabolism,2022,42(01):191.[doi:10.3760/cma.j.cn121383-20210326-03036]